Evaluating only Sano’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Donal Doyle founded Sano in London to develop non-invasive continuous glucose monitoring for wellness optimization.
FUNDING
Raised £25M in Series A funding; began clinical trials of patch-based optical glucose sensing technology.
REGULATORY ACTION
CE marking submission revealed accuracy gaps versus finger-prick standards; failed to meet EU MDR requirements.
SHUTDOWN
Ran out of funding after failing to achieve regulatory-grade accuracy; shut down without launching a commercial product.
Full Analysis
Free · no account needed
Documented cause
Sano, a London-based startup developing a non-invasive continuous glucose monitor for non-diabetics, raised £25M but failed to demonstrate sufficient clinical accuracy in regulatory submissions. Founder Donal Doyle had positioned the device as a wellness tool for metabolic health optimization, but the CE marking process revealed accuracy gaps versus gold-standard finger-prick tests. The company burned through its funding trying to solve the physics of non-invasive optical glucose sensing and shut down in 2022 without bringing a product to market.
Lesson
“Hardware health startups must validate core physics feasibility before raising significant capital for regulatory pathways.”